Although the significance of cathepsin G (CTSG) in host defense has been intensively investigated, little is known about its potential roles in granulopoiesis or leukemogenesis. We report here that CTSG is directly targeted and suppressed by AML1-ETO in t(8;21) acute myeloid leukemia (AML). Luciferase assays demonstrate that the CTSG promoter is strongly transactivated by AML1 and the AML1-dependent transactivation is suppressed by AML1-ETO. We also define a novel regulatory mechanism by which AML1-ETOmediated transrepression requires both AML1-ETO and AML1 binding at adjacent sites, instead of the replacement of AML1 by AML1-ETO, and wild-type AML1 binding is a prerequisite for the repressive effect caused by AML1-ETO. Further evidence shows that CTSG, as a hematopoietic serine protease, can degrade AML1-ETO both in vitro and in vivo. Restoration of CTSG induces partial differentiation, growth inhibition and apoptosis in AML1-ETO-positive cells. In addition to t(8;21) AML, CTSG downregulation is observed in AML patients with other cytogenetic/genetic abnormalities that potentially interrupt normal AML1 function, that is, inv(16) and EVI1 overexpression. Thus, the targeting and suppression of CTSG by AML1-ETO in t(8;21) AML may provide a mechanism for leukemia cells to escape from the intracellular surveillance system by preventing degradation of foreign proteins.
INTRODUCTION
The t(8;21) translocation is one of the most common chromosomal abnormalities in acute myeloid leukemia (AML), present in over 10% of AML cases and 40% of subtype M2 (AML-M2) cases based on the French-American-British classification. 1 The AML1-ETO fusion protein generated by this translocation contains the N-terminal DNA-binding domain (Runt domain) of AML1 (also known as RUNX1) and the repression domain of the almost fulllength ETO (also known as MTG8). AML1, a key transcription factor for definitive hematopoiesis, 2 regulates a wide spectrum of genes essential for various molecular functions, such as growth-factor receptors, 3 enzymes and cytokines, 4, 5 whereas ETO is a transcriptional corepressor that associates with various repressor proteins, including NCoR/SMRT, HDACs and mSin3a.
6 AML1-ETO may have a critical and initiating role in the processes that can lead to leukemic transformation, possibly through suppressing normal AML1 function in a dominant-negative manner 7, 8 to cause myelodysplasia 8 or through inhibiting apoptosis of hematopoietic progenitors.
9,10 AML1-ETO is also reported to interact with other important hematopoietic transcription factors, such as PU.1, Gfi-1 and C/EBPa, and hence has the potential to alter the expression of genes regulated by these transcription factors. [11] [12] [13] Because AML1-ETO is believed to be a key factor for leukemogenesis in t(8;21)-associated AML, 14 much interest has been focused on the study of AML1-ETO-target genes over the past two decades, yielding many important insights into the pathogenesis of AML1-ETO-positive leukemia.
Pathologically, t(8;21) AML is characterized by a blockage of granulopoiesis at the myeloblast-promyelocyte stage that is featured by the presence of prominent azurophil granules. 15 Under physiological conditions, azurophil granules characteristically contain neutrophil serine proteases, that is, neutrophil elastase (ELA2), proteinase 3 (PR3) and cathepsin G (CTSG). 16 Indeed, ELA2 and PR3 have been reported to be predominantly expressed in t(8;21) AML, 17, 18 but little is known about CTSG in t(8;21) AML. More surprisingly, hidden information from genomewide studies has implied that CTSG expression might be deficient in t(8;21) AML and that AML1-ETO seems to influence CTSG expression. For example, transcriptome data from CD34 þ or U937 cells with the ectopic expression of AML1-ETO showed that CTSG appeared to be one of the most significantly downregulated genes. 19, 20 Furthermore, global gene-expression profiling of t(8;21)-positive cells with AML1-ETO-knockdown expression demonstrated that CTSG expression could be raised by AML1-ETO suppression. 21 Therefore, we here investigated the precise mechanism underlying the transcriptional regulation between CTSG and AML1-ETO, as well as the potential role of CTSG in leukemogenesis of t(8;21) AML.
CTSG is usually thought to be involved in host defense and immune response provided by neutrophils. 22 On the other hand, because of its granulopoiesis-specific expression pattern, CTSG has also been implicated in several important hematopoietic processes including differentiation and apoptosis. For instance, CTSG cleaves full-length STAT5a to generate the C-terminal truncated form STAT5g, which is involved in myeloid cell differentiation. 23 CTSG participates in apoptosis of NB4 cells, an acute promyelocytic leukemia cell line, through cleavage of the human brm protein, which is part of a complex believed to regulate chromatin conformation. 24 In this study, we showed that CTSG was directly targeted and suppressed by AML1-ETO in t(8;21) AML. Functionally, we also demonstrated that CTSG was able to degrade the AML1-ETO fusion protein in vitro and in vivo. Furthermore, the exogenous restoration of CTSG in AML1-ETO-positive Kasumi-1 cells induced partial differentiation, growth inhibition and apoptosis. Our results suggest that CTSG deficiency may contribute to the leukemogenesis of t(8;21)-positive AML.
RESULTS
Inverse correlation between CTSG and AML1-ETO expression at both the mRNA and protein levels Primarily based on subtle information gleaned from previous publications, 20, 21, 25 we hypothesized that CTSG expression may have an inverse relationship with AML1-ETO expression in t(8;21) AML cells. To test this hypothesis, we performed quantitative realtime reverse transcription PCR (RT-PCR) and western blot to measure CTSG expression in AML1-ETO-positive cell lines (Kasumi-1 and SKNO-1) versus AML1-ETO-negative cell lines (U937 and HL60). As illustrated in Figures 1a and b , CTSG expression in AML1-ETO-positive cells was significantly lower than that in AML1-ETOnegative cells at both the mRNA and protein levels, supporting our hypothesis that CTSG expression is inversely correlated with AML1-ETO expression. To confirm this inverse correlation, we employed a widely used AML1-ETO-inducible cell line, U937-A/E9/ 14/18 cells, 26 and detected changes in CTSG expression over a time course of AML1-ETO induction. As shown in Figures 1c and d , AML1-ETO induction repressed CTSG expression. Collectively, these results revealed that CTSG expression is inversely correlated with AML1-ETO expression at both the mRNA and protein levels, implicating that CTSG transcription may be suppressed by AML1-ETO.
AML1-ETO represses AML1-dependent transactivation of the CTSG promoter, and both the DNA-binding domain and the corepressor interaction domain of AML1-ETO are required To further address the question of whether the repression of CTSG expression in t(8;21) cells is directly mediated by AML1-ETO, we cloned the CTSG promoter sequence ( À 628 to þ 56 bp) into a pGL3-basic vector and monitored luciferase activity in several hematopoietic and non-hematopoietic cell lines. As shown in Figure 2a , promoter activity of CTSG was significantly lower in nonhematopoietic cells (HeLa or 293T) than in hematopoietic cells, which is consistent with the previous finding that the CTSG promoter directs its hematopoietic-specific expression. 27 More importantly, we found that CTSG promoter activity was prominently higher in AML1-ETO-negative leukemia cells (U937 or NB4) than in AML1-ETO-positive leukemia cells (Kasumi-1 or SKNO-1) (Figure 2a ), suggesting that AML1-ETO is a key factor in suppressing CTSG promoter activity in t(8;21)-positive cells. These results were also consistent with the lower expression levels of endogenous CTSG observed in AML1-ETO-positive cells ( Figures  1a and b) .
To investigate the separate influences of AML1 and AML1-ETO on CTSG expression, we performed luciferase assays in non-hematopoietic HeLa cells lacking endogenous AML1 and AML1-ETO. 28 As shown in Figure 2b , CTSG promoter activity increased in a dose-dependent manner when only AML1 was transfected, whereas transfection with AML1-ETO alone caused minor/minimal changes in promoter activity (Figure 2c ), indicating that transactivation of the CTSG promoter is AML1-dependent. More importantly, AML1-dependent transactivation was significantly suppressed by AML1-ETO (Figure 2d ) after cotransfection with AML1 and AML1-ETO in HeLa cells, suggesting that the reduced promoter activity observed in AML1-ETO-positive cells (Figure 2a ) is due to repression of AML1-dependent transactivation by AML1-ETO. Next, to identify the functional domains of AML1-ETO involved in transcriptional repression of the CTSG promoter, we constructed two AML1-ETO mutants: 28 (1) AML1-ETO-L148D (AE-L148D), which contains a point mutation in the Runt homology domain of the AML1 moiety and thus lacks DNA-binding activity and (2) AML1-ETOtr (AEtr), which lacks the corepressor interaction region. As shown in Figure 2d , both the mutants abolished AML1-ETOmediated repression of the CTSG promoter, indicating that the repression was due to both the DNA-binding domain and corepressor recruitment domain of AML1-ETO. The requirement of the DNA-binding domain for AML1-ETO-mediated transrepression also provides evidence that AML1-ETO binds to the CTSG promoter directly.
Two adjacent AML1-binding sites on the CTSG promoter, the À 134 site bound by AML1 and the À 152 site bound by AML1-ETO, are required for AML1-ETO-mediated repression To further investigate the regulatory elements within the CTSG promoter involved in AML1-dependent activation and AML1-ETOmediated repression, we performed a motif analysis of the CTSG promoter using the TRANSFAC database. 29 Four potential AML1-binding sites were identified upstream of the transcription start site (TSS) at positions À 487, À 475, À 152 and À 134 (Figure 3a) . To determine the functional sites for wild-type AML1 and AML1-ETO binding, these four sites were mutated separately and individually evaluated in U937 and Kasumi-1 cells using luciferase assays. In U937 cells, which endogenously express AML1 but not AML1-ETO, CTSG promoter activity was severely impaired only when the À 134 site was mutated, suggesting that this site is most likely bound by AML1 and responsible for AML1-dependent transactivation ( Figure 3b ). In contrast, in Kasumi-1 cells, endogenously expressing both AML1 and AML1-ETO, luciferase activity displayed a significant increase when the À 152 site was mutated as compared with the other mutants (Figure 3c ), suggesting that this site might be crucial for AML1-ETO-mediated repression. The influence of mutations appeared to be not strong in Kasumi-1 cells, probably due to the impaired function of many other hematopoietic transcription factors, such as PU.1 and C/EBPa.
1 Therefore, we cotransfected the AML1-ETO-expressing plasmid with the CTSG promoter or its mutants into U937 cells. As shown in Figure 3d , luciferase activity of the wild-type promoter was reduced by almost 75% by AML1-ETO (lane 2 vs 1), consistent with the above finding of AML1-ETO-mediated repression. Mutation of the À 152 site displayed a dramatic loss on AML1-ETO-mediated transrepression (lane 8/7 vs 2/1), confirming that the À 152 site is the major regulatory element bound by AML1-ETO and critical for AML1-ETO repression. Moreover, promoter activity of the À 134 mutant was also not significantly repressed by AML1-ETO (lane 10 vs 9), which might be attributable to the loss of AML1-dependent transactivation due to the impaired AML1 binding to the À 134 site (lane 9 vs 1). In addition, we performed luciferase assays in HeLa cells lacking both endogenous AML1 and AML1-ETO, and the results also validated the above findings (Supplementary Figure S1) . A mutant form of AML1, AML1-L175D, which cannot bind to DNA, 28 was also included, further supporting the observation that AML1 binding and activation of the CTSG promoter is a prerequisite for AML1-ETO repression of AML1-ETO represses CTSG expression and function W Jin et al AML1-dependent transactivation. Therefore, we conclude that AML1-ETO-mediated transrepression of the CTSG promoter requires both AML1-ETO binding at the À 152 site and wildtype AML1 binding at the À 134 site.
Both AML1 and AML1-ETO bind to the CTSG promoter in vivo One important question that still remains to be answered is whether AML1-ETO and AML1 directly target the CTSG promoter in t(8;21) AML cells. To address this question, we performed chromatin immunoprecipitation (ChIP)-PCR assays using two primer sets covering À 487/ À 475 and À 152/ À 134 sites in U937 or Kasumi-1 cells using anti-AML1 (N20), anti-AML1 (C19) and anti-ETO (C20) antibodies (Figure 4a ). The anti-AML1 (N20) antibody can recognize both AML1 and AML1-ETO, the anti-AML1 (C19) antibody can recognize AML1 but not AML1-ETO and the anti-ETO (C20) antibody specifically recognizes AML1-ETO. An irrelevant region downstream of TSS was selected as a negative control. As shown in the upper panel of Figure 4b , AML1 binding was specifically detected at the À 152/ À 134 sites in U937 cells when the anti-AML1 (N20) or anti-AML1 (C19) antibody was used. In Kasumi-1 cells expressing both AML1 and AML1-ETO, positive bands were amplified at the À 152/ À 134 sites from all three immunoprecipitations (Figure 4b , lower panel), indicating that both AML1 and AML1-ETO are present at the CTSG promoter in Kasumi-1 cells. In contrast, the enrichment was not achieved at the À 487/ À 475 sites in both U937 and Kasumi-1 cells (Figure 4b ), indicating neither AML1 nor AML1-ETO binding at these sites. These ChIP data are consistent with the luciferase results shown in Figures 3c and d and provide in vivo evidence that AML1 and AML1-ETO both bind to the endogenous CTSG promoter.
CTSG degrades the AML1-ETO fusion protein Because the function of CTSG is generally associated with its proteolytic activity, we hypothesize that low CTSG expression in AML1-ETO-positive leukemia cells may prevent CTSG-mediated degradation of the pathogenic AML1-ETO fusion protein. To test our hypothesis, we assayed whether AML1-ETO could be a substrate of CTSG. We incubated in vitro-translated AML1-ETO with increasing amounts of purified human CTSG and assessed AML1-ETO cleavage by western blot. As shown in Figures 5a and b, AML1-ETO degradation correlated with the amounts of CTSG in a dose-dependent manner. We also performed the incubation in the presence of phenylmethylsulfonyl fluoride (PMSF), a serine protease inhibitor, and found that AML1-ETO degradation was significantly reduced (Figures 5a and b) , suggesting that AML1-ETO is cleaved by CTSG. To further evaluate the proteolytic processing of endogenous AML1-ETO, we treated Kasumi-1 nuclear extracts with increasing amounts of CTSG. As illustrated in Figures 5c and d, similar cleavage patterns were observed as those obtained from in vitro-translated products. It was worthy to be pointed out that large amounts of CTSG seemed to cleave AML1 in vitro as well. However, the cleavage sensitivity of CTSG on AML1 was much lower than that on (Figure 2b ), indicating that CTSG and AML1 can coexist under physiological conditions. Although much remains to be elucidated about the potential mechanisms of CTSG action, our results suggest that AML1-ETO may be a proteolytic substrate of CTSG.
Induction of partial differentiation, growth inhibition and apoptosis in t(8;21) cells with the ectopic expression of CTSG Based on the above findings that AML1-ETO suppressed CTSG expression and CTSG could cleave AML1-ETO, we hypothesized that the ectopic expression of CTSG in AML1-ETO-positive leukemic cells would cause degradation of the endogenous AML1-ETO and relieve the oncogenic effects of AML1-ETO. To test our hypothesis, we first transfected the CTSG-expressing plasmid into Kasumi-1 cells and detected AML1-ETO by western blot. A mutant CTSG-expressing plasmid that lacks catalytic activity (CTSG/Gly201) 30 was also included as a negative control. As shown in Figure 6a , AML1-ETO was significantly degraded at 72 h post transfection in the cells with the wild-type CTSG, but not in those with the mutant CTSG. The data demonstrated that the cleavage of the AML1-ETO fusion protein was exclusively due to CTSG restoration. Furthermore, we tested the biological effects of CTSG restoration in Kasumi-1 cells. CD11b is a conventional marker for assessing neutrophilic differentiation. The cells with the enforced expression of CTSG had an about 20% increase in CD11b expression, as compared with the cells with the empty vector (Figure 6b) . Such a moderate increase in cell differentiation seems to be consistent with the results obtained through targeting AML1-ETO by small interfering RNA. 31 Next, we performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and found that the viability of cells with the ectopic expression of CTSG was reduced as compared with the empty vector, indicating the occurrence of growth arrest after CTSG expression in Kasumi-1 cells (Figure 6c ). Furthermore, we examined the percentage of apoptosis after CTSG overexpression and found that apoptosis was increased in comparison with the control cells (Figure 6d ), which might contribute to the observed inhibition of proliferation. In addition, we performed cell-cycle analysis and found that the ectopic expression of CTSG did not affect the cell-cycle distribution (data not shown). Taken together, the results demonstrated that restoring CTSG in AML1-ETO-positive cells induced an in vivo proteolytic processing of AML1-ETO, and consequently triggered partial differentiation, growth arrest and apoptosis.
CTSG is downregulated in t(8;21) and other AML patients with functionally impaired AML1 Transcriptome data of AML have been accumulated over the past decade, providing useful resources for rapidly assessing the expression levels of genes of interest in large numbers of leukemia specimens. Accordingly, we retrieved three transcriptome data sets from previous studies [32] [33] [34] and assessed CTSG expression between t(8;21) and non-t(8;21) AML-M2 patient samples. Analysis of all the three data sets showed that CTSG expression was much lower in t(8;21) AML-M2 than that in non-t(8;21) AML-M2 (Figure 7a ), which was also validated by RT-PCR using fresh AML samples (Supplementary Figure S2) . These results collectively 
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indicate that CTSG is strongly suppressed by AML1-ETO in t(8;21) AML. We also compared the expression of other serine protease genes in azurophil granules, including ELA2, PR3 and AZU1, between t(8;21) and non-t(8;21) AML-M2 patient samples. As shown in Supplementary Figure S3 , CTSG was the only one whose expression was downregulated in t(8;21) AML-M2 patients among the neutrophil serine protease genes, further supporting our finding that CTSG is suppressed by AML1-ETO. To further elucidate whether CTSG suppression is influenced by other cytogenetic/genetic abnormalities, we assessed CTSG expression in 16 AML subgroups, which were previously defined through gene-expression signatures and largely coordinated with characteristic genetic or cytogenetic alterations. 32 As illustrated in Figure 7b , in addition to subgroup 13, which was characterized by t(8;21), subgroups 4, 9 and 10 showed lower CTSG expression as well. Subgroup 4 had a high frequency of CEBPA mutations and all the cases in this subgroup were classified as the M1 subtype. Because the M1 subtype is characterized by undifferentiated myeloblasts and few azurophil granules, it is therefore deducible that the expression levels of CTSG and other azurophil serine protease genes are probably low in this subtype. Indeed, ELA2, PR3 and AZU1 appeared to be expressed at low levels similar with CTSG (Supplementary Figure S4) . Moreover, subgroup 9 contained all the AML patients with inv (16) abnormality that generates the CBFb-MYH11 fusion gene, whereas subgroup 10 was mostly composed of patients with EVI1 overexpression. Because these two cytogenetic abnormalities have been reported to interrupt normal AML1 function, 35, 36 it is deducible that disruption of AML1 function by other abnormalities can repress CTSG expression as well.
DISCUSSION
The AML1-ETO fusion protein has a critical role in the pathogenesis of t(8;21) AML. Numerous in vivo and in vitro studies have demonstrated that AML1-ETO is a key and early event in the development of t(8;21)-positive leukemia through disrupting the normal hematopoietic cell differentiation and inducing abnormally high self-renewal capacity of hematopoietic progenitors. 14, 37, 38 Moreover, emerging evidence has shown that the intracellular surveillance system serves as an important safeguard against malignant transformation and destruction of this system may promote the genesis of leukemia. 39 To defeat or evade the surveillance system, leukemia cells may acquire some particular characteristics so as to favor the development of leukemia. For instance, the AML1-ETO fusion protein can repress the expression of major histocompatibility complex class I genes, thereby rendering the leukemia cells invisible to immune surveillance. 40 In this study, we show that AML1-ETO directly binds and suppresses the expression of CTSG that has the potential to degrade the AML1-ETO fusion protein. Our findings suggest that the direct targeting and suppression of CTSG by AML1-ETO may contribute to the pathogenesis of t(8;21)-positive leukemia, possibly through preventing CTSG-mediated degradation of the pathogenic AML1-ETO fusion protein and thereby promoting the leukemic effects of AML1-ETO.
Our results provide new insights into the complicated transcriptional regulatory mechanism underlying AML1-ETOmediated repression in t(8;21) AML. Because AML1-ETO retains the DNA-binding domain of AML1, it is generally believed that AML1-ETO binds to the same DNA sequence as the wild-type AML1 does or binds to the duplicated AML1 motifs, as recently suggested. 41 However, our results show that the truly functional binding sites of AML1-ETO in the CTSG promoter might be different from those of wild-type AML1. Luciferase assays indicated that the À 134 and À 152 sites in the CTSG promoter were responsible for AML1-dependent transactivation and AML1-ETO-mediated transrepression, respectively. The ChIP-PCR data also indicated that AML1 and AML1-ETO both bound to the CTSG promoter in Kasumi-1 cells (Figure 3b ). These observations demonstrated that although AML1-ETO and AML colocalized to the same chromatin, AML1-ETO did not competitively bind to the site occupied by AML1. Recent global ChIP-chip analyses of AML1 and AML1-ETO binding have shown that AML1-ETO preferentially binds to the wild-type AML1 targets and does not displace the wild-type AML1 (Gardini et al. 20 ). Our study not only provides direct evidence to support the above findings but also further reveals that AML1-ETO binds to an adjacent site to the wild-type AML1-binding site so as to exert its inhibitory effects on CTSG expression. In addition, we found that AML1 binding on the CTSG promoter was a prerequisite for the repressive effect exerted by AML1-ETO. The loss of AML1 binding largely weakened AML1-ETO-mediated transrepression of the CTSG promoter (Figure 3d ), which further verified our finding that AML1, not be replaced by AML1-ETO, was also present on the CTSG promoter. This novel regulatory pattern related to AML1-ETO and AML1 not only complements previous research but also opens up new avenues into understanding the complex mechanism of AML1-ETO-mediated repression.
In addition to t(8;21) AML-M2, downregulated CTSG expression was also observed in AML patients with other cytogenetic/genetic abnormalities that interrupt normal AML1 function, such as inv (16) abnormalities and the overexpression of EVI1. This observation may shed light on the importance of CTSG deficiency in these groups of leukemia. For example, CBFb, a native heterodimeric partner of AML1, is known to form a coactivator complex with AML1, whereas the formation of CBFb-MYH11 is likely to functionally impair AML1, probably through sequestration of AML1 into an inactive complex. 35 Also, EVI1 overexpression is oncogenic in hematopoietic cells, possibly due to its ability to interact with a number of crucial transcription factors, including AML1. It has been reported that the interaction between EVI1 and AML1 may reduce the DNA-binding affinity of AML1, thus impairing the activation capacity of AML1 (Senyuk et al. 36 ).Indeed, CTSG has been found to be specifically downregulated by EVI1 in 32Dcl.3 cells and bone marrow progenitors transfected with EVI1 (Laricchia-Robbio et al. 42 ). Although functional impairment of AML1 in the above two subgroups of AML patients has been suggested previously, evidence for the involvement in AML1-target genes, to the best of our knowledge, has not yet been reported.
Of note, selective destruction of aberrant proteins is an essential mechanism that cells use to ensure the homeostasis of intracellular proteins. Within cells, proteases have important roles in preventing the accumulation of aberrant, potentially toxic proteins. This process is of particular importance in protecting cells against harsh or diseased conditions, including malignancies. The cleavage assays shown here demonstrated that CTSG is capable of degrading AML1-ETO. CTSG repression by AML1-ETO may favor AML1-ETO escaping from CTSG-mediated cleavage. Recent attention to the role of the cathepsin family of lysosomal proteases in the disease process of leukemogenesis has provided valuable insights into the mechanisms of leukemogenesis and associated therapeutic directions. For example, arsenic trioxide, a promising therapeutic agent for treating acute promyelocytic leukemia, induces the release of cathepsin L, which contributes to the degradation of the PML-RARa fusion protein. 43 Similarly, imatinib, a leading compound used to treat patients with chronic myelogenous leukemia, induces the activation of cathepsin B, which directly triggers BCR-ABL degradation. 44 Our results also demonstrated that restoration of CTSG expression in t(8;21)-positive cells not only resulted in the cleavage of AML1-ETO, more importantly, but also induced partial differentiation, proliferation inhibition and apoptosis. These observations suggest that a therapeutic approach associated with AML1-ETO cleavage could potentially enhance the treatment of t(8;21) AML. Indeed, several drugs, such as eriocalyxin B, 45 oridonin 46 and the histone deacetylase inhibitor depsipeptide, 47 have shown therapeutic potential in t(8;21) AML by promoting the degradation of AML1-ETO. Accordingly, we tentatively propose that reconstitution of CTSG expression in t(8;21) leukemic cells may represent a new direction in the development of more sophisticated treatment protocols.
MATERIALS AND METHODS

Cell lines and drug treatment
HeLa and 293T cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) containing 10% fetal calf serum (Gibco). Kasumi-1, U937, U937-A/E9/14/18, NB4 and HL60 cells were cultured in RPMI 1640 (Gibco) containing 10% fetal calf serum. SKNO-1 cells were cultured in RPMI 1640 containing 10% fetal calf serum and 10 ng/ml granulocyte-macrophage colony-stimulating factor. U937-A/E9/14/18 cells were treated with 5 mM ponasterone A (Invitrogen, Carlsbad, CA, USA) to induce AML1-ETO expression.
RNA extraction and quantitative real-time RT-PCR Total RNA was extracted from cells using TRIzol reagent (Invitrogen) and converted to cDNA by SuperScript II reverse transcritptase (Invitrogen). quantitative real-time RT-PCR analysis and primers used are given in the Supplementary Information.
Western blot
To measure AML1-ETO and CTSG expression in different cell lines, total protein extracts and western blot analysis were performed as previously described. 48 
Plasmids
The CTSG promoter region was PCR-amplified from U937 cells and cloned into the luciferase reporter pGL3-basic vector, generating the plasmid CTSG(WT). Human CTSG cDNA was amplified from U937 cells by real-time RT-PCR and cloned into the pIRES2-EGFP and pcDNA3.1 vector (Clontech, Palo Alto, CA, USA). Primers for cloning are listed in Supplementary Table  S1 . Mutation of putative AML1-binding sites on CTSG(WT) and the construction of pIRES2-EGFP-CTSG/Gly201 were performed using QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. Primers for mutagenesis are listed in Supplementary Table S2. Reporter assay HeLa and 293T cells were transfected using Lipofectamine 2000 (Invitrogen). U937, NB4, Kasumi-1 and SKNO-1 cells were transfected using an ECM830 electroporator (BTX, Holliston, MA, USA). Luciferase activity was detected by the Dual Luciferase Assay Kit (Promega, Madison, WI, USA). The details were described previously. 49 ChIP-PCR assay ChIP was performed according to the Affymetrix (Santa Clara, CA, USA) protocol with anti-AML1 (N20, Santa Cruz Biotechnology, Santa Cruz, CA), anti-ETO (C20, Santa Cruz Biotechnology) and anti-AML1 (C19, Calbiochem, Mendon, France) antibodies, as well as non-specific IgG (Santa Cruz Biotechnology). Primers for PCR are listed in Supplementary Table S1 .
In vitro transcription/translation
The pSG5-AML1-ETO plasmid encoding AML1-ETO was transcribed and translated using the TnT Quick Coupled Transcription/Translation Systems (Promega) in accordance with the manufacturer's recommendations.
In vitro cleavage assay
In vitro-translated AML1-ETO or Kasumi-1 nuclear proteins were incubated with purified human CTSG as described previously. 50 The details are shown in the Supplementary Information.
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MTT assay
MTT assays were preformed as previously described 51 with modifications described in the Supplementary Information.
Differentiation and apoptosis analysis
Annexin V was used to detect apoptotic cells and cell-surface CD11b expression was used to assess myeloid differentiation. The details are available in the Supplementary Information.
Statistical analysis
The data were analyzed statistically using Student's t-test.
